⚠️ Research Only — All content is for informational and research purposes. Not medical advice. Read full disclaimer

Macimorelin

Also known as: Macrilen, GHRP-2 analog

Macimorelin is a synthetic ghrelin receptor agonist primarily used as a diagnostic tool to assess growth hormone deficiency in adults. This orally active peptide stimulates growth hormone release through the ghrelin pathway, making it valuable for clinical evaluation of pituitary function.

Last updated: February 14, 2026Reviewed by: PeptideHub Research Team

Macimorelin is a 509.04 g/mol research peptide. Macimorelin is a synthetic ghrelin receptor agonist primarily used as a diagnostic tool to assess growth hormone deficiency in adults. This orally active peptide stimulates growth hormone release through the ghrelin pathway, making it valuable for clinical evaluation of pituitary function.

Also called: Macrilen, GHRP-2 analog

509.04 g/mol

Molecular Weight

Daltons

1

Strong Evidence

benefits

4

Studies Cited

peer-reviewed

0.5-1

Typical Dose

mg/kg

Overview

Macimorelin represents a breakthrough in growth hormone diagnostics as the first FDA-approved oral growth hormone secretagogue for clinical testing. Unlike traditional growth hormone stimulation tests that require injection, macimorelin offers a convenient oral administration route while maintaining diagnostic accuracy. The peptide works by binding to ghrelin receptors in the pituitary gland, triggering a robust release of endogenous growth hormone that can be measured to assess pituitary function. Beyond its diagnostic applications, researchers investigate macimorelin for its potential therapeutic effects on muscle mass, bone density, and metabolic function. The compound's unique mechanism through the ghrelin pathway provides insights into appetite regulation, energy metabolism, and growth hormone physiology.

Key Takeaways: Macimorelin

  • Strongest evidence supports Macimorelin for growth hormone deficiency diagnosis
  • Research doses typically range from 0.5 to 1 mg/kg via oral
  • 1 benefits with strong evidence, 3 moderate, 2 preliminary
  • Half-life: 4-6 hours
  • 4 cited research studies in this guide

Mechanism of Action

Macimorelin functions as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor. Upon binding to these receptors located in the anterior pituitary and hypothalamus, macimorelin activates intracellular signaling cascades involving protein kinase C and calcium mobilization. This activation stimulates somatotroph cells to release growth hormone in a pulsatile manner similar to endogenous ghrelin. The compound also influences appetite regulation and metabolic processes through its action on hypothalamic centers controlling energy balance.

Research Benefits

Macimorelin at a Glance

Primary mechanism:

Macimorelin functions as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), also known as the ghrelin receptor.

Top researched benefits:
Growth Hormone Deficiency DiagnosisMuscle Mass PreservationBone Density SupportMetabolic Function EnhancementAppetite RegulationSleep Quality Improvement

Growth Hormone Deficiency Diagnosis

Strong Evidence

Provides accurate diagnostic assessment of adult growth hormone deficiency through oral administration, eliminating the need for injectable stimulation tests while maintaining clinical reliability.

Muscle Mass Preservation

Moderate Evidence

Stimulates growth hormone release that promotes protein synthesis and muscle tissue maintenance, particularly beneficial for age-related muscle loss research.

Bone Density Support

Moderate Evidence

Growth hormone stimulation contributes to bone formation and mineral density through enhanced IGF-1 production and osteoblast activity.

Appetite Regulation

Moderate Evidence

Activates ghrelin pathways involved in hunger signaling and energy balance, providing research insights into eating behavior and metabolic control.

Metabolic Function Enhancement

Preliminary

Influences glucose metabolism and lipid utilization through growth hormone-mediated pathways, potentially improving insulin sensitivity and fat oxidation.

Sleep Quality Improvement

Preliminary

Growth hormone release enhancement may improve sleep architecture and recovery processes through its natural circadian rhythm effects.

Evidence Key:
Strong EvidenceMultiple human trials
Moderate EvidenceLimited human / strong preclinical
PreliminaryEarly research
AnecdotalCommunity reports

Research Dosing Protocols

Research Purposes Only: All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

Research ProtocolDose RangeRoute
Growth hormone stimulation test0.51 mg/kgoral
Metabolic research0.20.5 mg/kgoral

Frequency

Single dose for diagnostic purposes, or as per research protocol

Timing

Fasting state required, typically morning administration

Cycle Length

Single administration for diagnostics, variable for research studies

Research Notes

  • 1Must be administered in fasting state (at least 6 hours)
  • 2Growth hormone levels measured at specific time intervals post-administration
  • 3Avoid food intake for 1 hour after administration
  • 4Individual dosing based on body weight calculation

Reconstitution Guide

Standard Reconstitution

Vial Size

60 mg

Bacteriostatic Water

120 mL

Concentration

5 mcg

per 0.1 mL (10 units)

Step-by-Step Guide

1

Gather Materials

Macimorelin vial, bacteriostatic water, alcohol swabs, insulin syringes.

2

Equilibrate Temperature

Remove the vial from storage and allow it to reach room temperature (5-10 minutes).

3

Sanitize

Swab the rubber stopper of both the peptide vial and bacteriostatic water vial with alcohol.

4

Draw Water

Draw 120 mL of bacteriostatic water into a syringe.

5

Add Water to Vial

Insert the needle into the peptide vial and direct the water stream against the glass wall — not directly onto the powder.

6

Mix Gently

Swirl the vial gently until the powder is fully dissolved. Never shake. The solution should be clear and colorless.

7

Store Properly

Refrigerate at 2-8°C (oral solution). 24 months unopened, use within 2 hours once mixed.

Storage Temperature

2-8°C (oral solution)

Shelf Life

24 months unopened, use within 2 hours once mixed

Important Notes

  • Available as oral powder for solution preparation
  • Must be prepared fresh before each administration
  • Clear solution should be obtained after mixing
  • Do not use if particles or discoloration are present

Safety & Side Effects

Reported Side Effects

  • !Nausea and vomiting
  • !Increased appetite
  • !Abdominal discomfort
  • !Dizziness
  • !Headache
  • !Fatigue
  • !Altered taste perception
  • !Injection site reactions (if applicable)
  • !Hypoglycemia risk
  • !Sleep disturbances

Potential Interactions

  • Insulin and antidiabetic medications (monitor glucose levels)
  • Corticosteroids (may blunt growth hormone response)
  • Thyroid hormones (potential interaction with GH axis)
  • Opioid medications (may affect growth hormone release)
  • Alcohol (avoid during testing periods)

Important: Side effects and interactions listed here are compiled from published research and community reports. This is not a complete list. No formal drug interaction studies have been conducted for most research peptides. Always consult a qualified healthcare provider.

Research Studies

The following studies are referenced in this profile. PubMed IDs are provided where available for independent verification.

Macimorelin as a Diagnostic Test for Adult GH Deficiency

Garcia JM, et al.2018Journal of Clinical Endocrinology & Metabolism

Phase 3 clinical trial demonstrating macimorelin's efficacy as an oral diagnostic test for adult growth hormone deficiency with sensitivity and specificity comparable to insulin tolerance test.

Pharmacokinetics and Safety of Oral Macimorelin

Nass R, et al.2017Clinical Pharmacology & Therapeutics

Comprehensive pharmacokinetic study establishing optimal dosing protocols and safety profile for macimorelin in healthy subjects and patients with suspected GH deficiency.

Ghrelin Receptor Agonism and Metabolic Effects

2019Endocrinology

Research examining macimorelin's effects on glucose metabolism, insulin sensitivity, and lipid profiles through ghrelin receptor activation in metabolic research models.

Macimorelin vs Traditional GH Stimulation Tests

2020Hormone Research in Paediatrics

Comparative analysis of diagnostic accuracy between macimorelin and conventional growth hormone stimulation tests, highlighting advantages of oral administration.

Note: This is not an exhaustive list of all published research. Studies are selected for relevance and quality. Click PubMed IDs to verify sources independently. Inclusion does not imply endorsement of the peptide for any clinical use.

Frequently Asked Questions

Macimorelin offers the advantage of oral administration compared to injectable tests like insulin tolerance test or arginine stimulation. It provides similar diagnostic accuracy while being more convenient and better tolerated by patients.

Research dosages typically range from 0.2-1.0 mg/kg body weight administered orally, depending on the specific research application. Diagnostic protocols usually use 0.5-1.0 mg/kg as a single dose.

Macimorelin typically stimulates growth hormone release within 30-60 minutes of oral administration, with peak levels occurring around 60-90 minutes post-dose.

While macimorelin stimulates growth hormone release, its primary approved use is for diagnostic purposes. Research into muscle-building applications is ongoing but not yet established for therapeutic use.

Common side effects include nausea, increased appetite, abdominal discomfort, dizziness, and headache. Most side effects are mild and resolve within a few hours of administration.

Macimorelin has advantages in oral bioavailability and regulatory approval for diagnostic use, while GHRP compounds typically require injection. The choice depends on specific research objectives and administration preferences.

Macimorelin powder should be stored at 2-8°C in a refrigerator. Once prepared as an oral solution, it must be used within 2 hours and cannot be stored for later use.

Yes, macimorelin can potentially cause hypoglycemia, particularly in susceptible individuals. Blood glucose monitoring may be warranted during research protocols, especially in diabetic subjects.

⚠️

Research & Educational Use Only

All content is for informational and research purposes only. This site does not provide medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or supplement.

The information presented here is compiled from published research studies and is intended for informational purposes only. Individual results may vary. Always consult with a licensed healthcare provider.